These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6137850)

  • 1. Plasma homovanillic acid and tardive dyskinesia during neuroleptic maintenance and withdrawal.
    Kirch D; Hattox S; Bell J; Murphy R; Freedman R
    Psychiatry Res; 1983 Jul; 9(3):217-23. PubMed ID: 6137850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tardive dyskinesia and plasma homovanillic acid.
    Moore DC; Glazer WM; Bowers MB; Heninger GR
    Biol Psychiatry; 1983 Dec; 18(12):1393-402. PubMed ID: 6140961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia.
    Glazer WM; Bowers MB; Charney DS; Heninger GR
    Biol Psychiatry; 1989 Jul; 26(3):224-33. PubMed ID: 2568132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship of circulating estradiol to tardive dyskinesia in men and postmenopausal women.
    Glazer WM; Naftolin F; Moore DC; Bowers MB; MacLusky NJ
    Psychoneuroendocrinology; 1983; 8(4):429-34. PubMed ID: 6144123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative neurochemical investigation of tardive dyskinesia and neuroleptic-induced chronic parkinsonism.
    Arató M; Bagdy G; Perényi A; Béla A
    Psychiatry Res; 1984 Apr; 11(4):347-51. PubMed ID: 6146151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurochemical studies on tardive dyskinesia. I. Urinary homovanillic acid and plasma prolactin.
    Tripodianakis J; Markianos M; Garelis E
    Biol Psychiatry; 1983 Mar; 18(3):337-45. PubMed ID: 6132625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effect of haloperidol and clozapine on plasma homovanillic acid in elderly schizophrenic patients with or without tardive dyskinesia.
    Andia I; Zumarraga M; Zabalo MJ; Bulbena A; Davila R
    Biol Psychiatry; 1998 Jan; 43(1):20-3. PubMed ID: 9442340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients.
    Kirch DG; Jaskiw G; Linnoila M; Weinberger DR; Wyatt RJ
    Psychiatry Res; 1988 Sep; 25(3):233-42. PubMed ID: 2903509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma HVA, tardive dyskinesia and psychotic symptoms in long-term drug-free inpatients with schizophrenia.
    Muscettola G; Barbato G; de Bartolomeis A; Monteleone P; Pickar D
    Psychiatry Res; 1990 Sep; 33(3):259-67. PubMed ID: 2243901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma drug and homovanillic acid levels in psychotic patients receiving neuroleptics.
    Harris PQ; Brown SJ; Friedman MJ; Bacopoulos NG
    Biol Psychiatry; 1984 Jun; 19(6):849-60. PubMed ID: 6146355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.
    Morgenstern H; Glazer WM
    Arch Gen Psychiatry; 1993 Sep; 50(9):723-33. PubMed ID: 8102845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients.
    Csernansky JG; Kaplan J; Holman CA; Hollister LE
    Psychopharmacology (Berl); 1983; 81(2):115-8. PubMed ID: 6138793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tardive dyskinesia in the aged. Duration of treatment relationships.
    Toenniessen LM; Casey DE; McFarland BH
    Arch Gen Psychiatry; 1985 Mar; 42(3):278-84. PubMed ID: 2858189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in mental condition, hyperkinesias and biochemical parameters after withdrawal of chronic neuroleptic treatment.
    Perényi A; Frecska E; Bagdy G; Révai K
    Acta Psychiatr Scand; 1985 Nov; 72(5):430-5. PubMed ID: 2868608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurochemical findings in the cerebrospinal fluid of schizophrenic patients with tardive dyskinesia and neuroleptic-induced parkinsonism.
    Saito T; Ishizawa H; Tsuchiya F; Ozawa H; Takahata N
    Jpn J Psychiatry Neurol; 1986 Jun; 40(2):189-94. PubMed ID: 2431183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients.
    Pickar D; Labarca R; Linnoila M; Roy A; Hommer D; Everett D; Paul SM
    Science; 1984 Aug; 225(4665):954-7. PubMed ID: 6474162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent neuroleptic therapy and tardive dyskinesia: a literature review.
    Goldman MB; Luchins DJ
    Hosp Community Psychiatry; 1984 Dec; 35(12):1215-9. PubMed ID: 6150891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life.
    Sweet RA; Mulsant BH; Gupta B; Rifai AH; Pasternak RE; McEachran A; Zubenko GS
    Arch Gen Psychiatry; 1995 Jun; 52(6):478-86. PubMed ID: 7771918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    McGrath JJ; Soares KV
    Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements.
    Tan YL; Zhou DF; Zhang XY
    Schizophr Res; 2005 May; 74(2-3):263-70. PubMed ID: 15722005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.